69 -4 (90) 2026 - Artikova S.G., Mamadjanov S.K. - THE COURSE OF INFLAMMATORY PROCESSES AND THEIR SIGNIFICANCE IN THE DEVELOPMENT OF METABOLIC DYSFUNCTION–ASSOCIATED FATTY LIVER DISEASE

THE COURSE OF INFLAMMATORY PROCESSES AND THEIR SIGNIFICANCE IN THE DEVELOPMENT OF METABOLIC DYSFUNCTION–ASSOCIATED FATTY LIVER DISEASE

Artikova S.G. - Andijan State Medical Institute

Mamadjanov S.K. - Andijan State Medical Institute

Primqulova G.N. - Andijan State Medical Institute

Abduraxmanov M.G. - Andijan State Medical Institute

Resume

Metabolic dysfunction–associated fatty liver disease (MAFLD) is currently considered one of the most common chronic liver diseases worldwide. Factors such as obesity, insulin resistance, diabetes mellitus, and metabolic syndrome play a significant role in its development. This article analyzes the course of inflammatory processes in the development of metabolic dysfunction–associated fatty liver disease and their importance in the pathogenesis of the disease. Studies show that inflammatory mediators, cytokines, and oxidative stress factors intensify morphological and functional changes in liver tissue. These processes contribute to the progression from simple steatosis to steatohepatitis and may further lead to liver fibrosis and cirrhosis. Early detection and control of inflammatory processes are therefore essential for preventing disease progression and selecting effective treatment strategies. The results of this study contribute to a deeper understanding of the pathogenetic role of inflammation in metabolic dysfunction–associated fatty liver disease and may help improve modern diagnostic and therapeutic approaches.

Keywords: metabolic dysfunction–associated fatty liver disease, inflammation, metabolic syndrome, insulin resistance, steatosis, steatohepatitis, cytokines, oxidative stress, liver fibrosis, pathogenesis.

First page

470

Last page

475

For citation:Artikova S.G., Mamadjanov S.K., Primqulova G.N., Abduraxmanov M.G. - THE COURSE OF INFLAMMATORY PROCESSES AND THEIR SIGNIFICANCE IN THE DEVELOPMENT OF METABOLIC DYSFUNCTION–ASSOCIATED FATTY LIVER DISEASE//New Day in Medicine 4(90)2026 470-475 https://newdayworldmedicine.com/en/new_day_medicine/4-90-2026

List of References

1. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330–344. doi:10.1038/nrgastro.2013.41.
2. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: A metabolic pathway to chronic liver disease. Hepatology. 2005;42(5):987–1000. doi:10.1002/hep.20920.
3. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: A practical approach to diagnosis and staging. Frontline Gastroenterol. 2014;5(3):211–218. doi:10.1136/flgastro-2013-100403.
4. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922. doi:10.1038/s41591-018-0104-9.
5. Loomba R, Adams LA. Advances in NAFLD therapeutics. Nat Rev Gastroenterol Hepatol. 2020;17(1):11–13. doi:10.1038/s41575-019-0267-9.
6. Mantovani A, Byrne CD, Scorletti E, Mantzoros CS, Targher G. Complications and outcomes of NAFLD and NASH. Nat Rev Gastroenterol Hepatol. 2021;18(4):257–267. doi:10.1038/s41575-020-00393-9.
7. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH. Hepatology. 2020;72(1):73–83. doi:10.1002/hep.29367.

   file

   download